Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K, likely an update, check for details.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on March 3, 2025, to report other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates Axsome Therapeutics is providing updates to the SEC, which could relate to significant business developments or financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard procedural update and does not contain information that inherently increases risk.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- March 03, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Axsome Therapeutics in this 8-K filing?
The provided text for the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.
When was this 8-K filing submitted to the SEC?
The filing was submitted on March 3, 2025, as indicated by 'Date of Report (Date of earliest event reported): March 03, 2025'.
What is Axsome Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at One World Trade Center, 22nd Floor, New York, New York, 10007.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
Does this filing include financial statements?
Yes, the filing is categorized under 'ITEM INFORMATION: Financial Statements and Exhibits', indicating that financial statements are included.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Axsome Therapeutics, Inc. (AXSM).